RU2008146718A - Способы лечения неврологических состояний с применением гематопоэтических факторов роста - Google Patents

Способы лечения неврологических состояний с применением гематопоэтических факторов роста Download PDF

Info

Publication number
RU2008146718A
RU2008146718A RU2008146718/15A RU2008146718A RU2008146718A RU 2008146718 A RU2008146718 A RU 2008146718A RU 2008146718/15 A RU2008146718/15 A RU 2008146718/15A RU 2008146718 A RU2008146718 A RU 2008146718A RU 2008146718 A RU2008146718 A RU 2008146718A
Authority
RU
Russia
Prior art keywords
neurological conditions
treating neurological
methods
application
growth factors
Prior art date
Application number
RU2008146718/15A
Other languages
English (en)
Inventor
Вольф-Рюдигер ШЕБИТЦ (DE)
Вольф-Рюдигер ШЕБИТЦ
Армин ШНАЙДЕР (DE)
Армин Шнайдер
Карола КРЮГЕР (DE)
Карола КРЮГЕР
Клеменс ЗОММЕР (DE)
Клеменс ЗОММЕР
Штефан ШВАБ (DE)
Штефан ШВАБ
Райнер КОЛЛЬМАР (DE)
Райнер КОЛЛЬМАР
Мартин МАУРЕР (DE)
Мартин МАУРЕР
Даниэла ВЕБЕР (DE)
Даниэла ВЕБЕР
Николаус ГАССЛЕР (DE)
Николаус ГАССЛЕР
Original Assignee
Аксарон Байосайенс Аг (De)
Аксарон Байосайенс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аксарон Байосайенс Аг (De), Аксарон Байосайенс Аг filed Critical Аксарон Байосайенс Аг (De)
Publication of RU2008146718A publication Critical patent/RU2008146718A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Psychology (AREA)

Abstract

1. G-CSF или его функционально активный вариант, который на 90% идентичен последовательности G-CFS человека, представленной как SEQ ID NО:28, для применения в способе лечения амиотрофического бокового склероза. ! 2. G-CSF по п.1, где G-CSF представляет собой G-CSF человека.

Claims (2)

1. G-CSF или его функционально активный вариант, который на 90% идентичен последовательности G-CFS человека, представленной как SEQ ID NО:28, для применения в способе лечения амиотрофического бокового склероза.
2. G-CSF по п.1, где G-CSF представляет собой G-CSF человека.
RU2008146718/15A 2002-12-31 2008-11-26 Способы лечения неврологических состояний с применением гематопоэтических факторов роста RU2008146718A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33175502A 2002-12-31 2002-12-31
US10/331,755 2002-12-31
US10/659,295 2003-09-11
US10/659,295 US7785601B2 (en) 2002-12-31 2003-09-11 Methods of treating neurological conditions with hematopoietic growth factors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005124277/15A Division RU2353385C2 (ru) 2002-12-31 2003-12-31 Способы лечения неврологических состояний с применением гематопоэтических факторов роста

Publications (1)

Publication Number Publication Date
RU2008146718A true RU2008146718A (ru) 2010-06-10

Family

ID=32710846

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008146718/15A RU2008146718A (ru) 2002-12-31 2008-11-26 Способы лечения неврологических состояний с применением гематопоэтических факторов роста

Country Status (8)

Country Link
US (8) US7785601B2 (ru)
EP (2) EP2186525A3 (ru)
JP (2) JP4733521B2 (ru)
CN (3) CN101926981A (ru)
AT (1) ATE450268T1 (ru)
AU (1) AU2009201467A1 (ru)
DE (1) DE60330390D1 (ru)
RU (1) RU2008146718A (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019082B2 (en) * 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
EP2095823A1 (en) * 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. GM-CSF for treating demyelination
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1581249B1 (en) * 2002-12-31 2009-12-02 Sygnis Bioscience GmbH & Co. KG G-csf for use in the treatment of amyotrophic lateral sclerosis
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
BRPI0410876B8 (pt) * 2003-06-02 2023-01-24 Evolutec Ltd composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
EP1817047B1 (en) * 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
JP2009505642A (ja) * 2005-08-19 2009-02-12 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション アラクノカンパのルシフェラーゼ
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20070196279A1 (en) * 2006-02-21 2007-08-23 Shen Che-Kun J Methods for treating progressive neurodegenerative disorders
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
WO2007105305A1 (ja) * 2006-03-14 2007-09-20 Japan Tobacco Inc. 新規なβ－ガラクトシド－α２，６－シアル酸転移酵素、それをコードする遺伝子およびその製造方法
JP5153114B2 (ja) 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
EP2089049A4 (en) * 2006-11-17 2011-11-16 Biogen Idec Inc SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
US8252555B2 (en) * 2006-12-29 2012-08-28 Evonik Degussa Ag Nucleic acid encoding a cobalamin-dependent methionine synthase polypeptide
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
WO2008137571A1 (en) * 2007-05-01 2008-11-13 Florida Atlantic University Methods of treating neurodegenerative diseases
JP4927774B2 (ja) * 2007-10-12 2012-05-09 サントリーホールディングス株式会社 Ｕｄｐ−グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
US8119367B2 (en) * 2007-10-22 2012-02-21 University Of Florida Research Foundation, Inc. Nucleic acids, compositions and uses thereof
TW200948964A (en) * 2008-04-17 2009-12-01 Novozymes As Laccase variants
US9132168B2 (en) * 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
KR20110068993A (ko) * 2008-08-05 2011-06-22 유니버시티 오브 사우스 플로리다 인지장애의 치료방법
SG10201807935SA (en) * 2008-09-04 2018-10-30 Abt Holding Co Use of stem cells to prevent neuronal dieback
WO2010049752A1 (en) 2008-10-31 2010-05-06 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
WO2010096446A1 (en) * 2009-02-17 2010-08-26 Marc Fisher Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
CA2768573C (en) * 2009-07-21 2020-09-15 Abt Holding Company A method for constructing a cell bank and a method for drug discovery
WO2011061304A1 (en) * 2009-11-20 2011-05-26 Pharnext New diagnostic tools for charcot-marie-tooth disease
BR112012012192A2 (pt) * 2009-11-25 2017-07-04 Codexis Inc b-glicosidades variantes recombinantes thermoascus aurantiacus para produção de açúcares fermentáveis a partir da biomassa celulósica
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
GB201011589D0 (en) * 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
US20130261165A1 (en) * 2010-12-16 2013-10-03 The Mclean Hospital Corporation Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN102212542B (zh) * 2011-04-11 2012-12-19 上海赛伦生物技术有限公司 重组马gmcsf的制备方法及相关马gmcsf核苷酸序列
US9399053B2 (en) * 2011-07-22 2016-07-26 The University Of Chicago Treatments for migraine and related disorders
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
WO2013036526A1 (en) * 2011-09-06 2013-03-14 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
US9632075B2 (en) * 2011-11-01 2017-04-25 Meselex, Inc. Prevention or attenuation of neuropathic pain by bile acids
US8889630B2 (en) * 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
CN104870634A (zh) * 2012-07-19 2015-08-26 宾夕法尼亚州研究基金会 再生用于在神经系统中治疗疾病和损伤的功能性神经元
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
CN115177637A (zh) 2013-04-12 2022-10-14 休斯顿卫理公会医院 改进用于移植的器官
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10039808B2 (en) * 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
EP4353320A3 (en) 2016-04-28 2024-05-15 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MA48480A (fr) 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CN108404118A (zh) * 2017-06-14 2018-08-17 张建宁 人源乳凝集素亚型蛋白的新用途
US10863912B2 (en) 2017-08-24 2020-12-15 Myneurva Holdings, Inc. System and method for analyzing electroencephalogram signals
AU2018348138A1 (en) 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
EP3870190A4 (en) 2018-10-26 2022-09-07 Alkahest, Inc. USE OF PLASMA AND PLASMA FRACTIONS TO REDUCE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY
WO2023154855A2 (en) * 2022-02-11 2023-08-17 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US5641663A (en) 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
ES2036530T3 (es) * 1986-01-22 1993-06-01 Chugai Seiyaku Kabushiki Kaisha Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena.
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5059909A (en) 1986-09-30 1991-10-22 Colloidal Dynamics Pty. Ltd. Determination of particle size and electrical charge
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5599690A (en) 1988-02-01 1997-02-04 Amgen Inc. Control of norleucine incorporation into recombinant proteins
US5021239A (en) 1988-03-21 1991-06-04 Genetics Institute, Inc. Use of M-CSF to improve lipoprotein cholesterol profiles
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ES2063783T3 (es) 1988-06-03 1995-01-16 Chugai Pharmaceutical Co Ltd Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion.
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5629283A (en) 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
EP0439952A3 (en) 1990-01-31 1992-09-09 Sgs-Thomson Microelectronics, Inc. Dual-port cache tag memory
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP2946231B2 (ja) 1990-05-31 1999-09-06 株式会社栗本鐵工所 超微粉分級機
JPH04198134A (ja) 1990-11-28 1992-07-17 Eisai Co Ltd 老人性痴呆症の治療・予防剤
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0661057A4 (en) * 1993-06-08 1997-09-03 Ajinomoto Kk ACCELERATOR OF THE PROLIFERATION OF HEMATOPIETIC CELLS.
US6465616B1 (en) * 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
DE19518505A1 (de) 1995-05-19 1996-11-21 Max Planck Gesellschaft Verfahren zur Genexpressionsanalyse
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
CA2213906A1 (en) * 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
US5895647A (en) * 1996-12-20 1999-04-20 The United States Of America As Represented By The Secretary Of The Navy Use of oral interleukin-6 as therapy for hemorrhagic shock
JP3503418B2 (ja) 1997-05-15 2004-03-08 ミノルタ株式会社 誘導加熱定着装置
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6093167A (en) 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
EP1019082B2 (en) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6537749B2 (en) 1998-04-03 2003-03-25 Phylos, Inc. Addressable protein arrays
JP2002516329A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション Ｇ−ｃｓｆ模倣物
CA2332318A1 (en) 1998-05-22 1999-12-02 Juan I. Luengo G-csf mimetics
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
DK1098664T3 (da) 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6261250B1 (en) 1998-08-20 2001-07-17 Rle Corporation Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation
US6610540B1 (en) 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
KR100689212B1 (ko) 1999-01-29 2007-03-09 암겐 인코포레이티드 Ｇｃｓｆ 결합체
AU1933401A (en) * 1999-12-03 2001-06-12 Human Genome Sciences, Inc. Cytokine receptor-like polynucleotides, polypeptides, and antibodies
DE10033219A1 (de) 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
JP2004512832A (ja) * 2000-09-01 2004-04-30 バイオアクタ・リミテッド 抗−血管新生ペプチド
JP2004524005A (ja) 2000-09-08 2004-08-12 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
AU2001286221B2 (en) 2000-09-13 2006-09-28 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
AU2002219830A1 (en) * 2000-11-10 2002-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
EP1723969B1 (en) 2001-03-12 2009-02-18 Institute of Gene and Brain Science Granulocyte-macrophage colony-stimulating factor (GM-CSF) as remedy for nerve damages
JP3763749B2 (ja) 2001-03-28 2006-04-05 独立行政法人科学技術振興機構 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞
US20020198150A1 (en) * 2001-06-07 2002-12-26 Ayelet Chajut Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
FR2834898B1 (fr) 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
DE10211063A1 (de) 2002-03-13 2003-10-09 Axaron Bioscience Ag Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo
AU2003240614A1 (en) 2002-05-10 2003-11-11 Ipf Pharmaceuticals Gmbh A method of inhibiting the emigration of cells from the intravascular compartment into tissues
NZ572388A (en) * 2002-05-17 2010-05-28 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
EP2095823A1 (en) 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. GM-CSF for treating demyelination
WO2004037196A2 (en) * 2002-10-24 2004-05-06 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP4198134B2 (ja) 2005-04-13 2008-12-17 京セラミタ株式会社 給紙装置
EP2036571A1 (de) * 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall

Also Published As

Publication number Publication date
US20080181865A1 (en) 2008-07-31
EP2186525A2 (en) 2010-05-19
US7785601B2 (en) 2010-08-31
US20090087481A1 (en) 2009-04-02
CN1756556A (zh) 2006-04-05
US20080175894A1 (en) 2008-07-24
US20080241097A1 (en) 2008-10-02
CN101926981A (zh) 2010-12-29
EP2186525A3 (en) 2011-02-09
CN100558397C (zh) 2009-11-11
JP4733521B2 (ja) 2011-07-27
AU2009201467A1 (en) 2009-05-14
JP2010270158A (ja) 2010-12-02
JP2006512419A (ja) 2006-04-13
US7884069B2 (en) 2011-02-08
US20080171080A1 (en) 2008-07-17
US8071543B2 (en) 2011-12-06
US20040141946A1 (en) 2004-07-22
US20080279814A1 (en) 2008-11-13
US20120231065A1 (en) 2012-09-13
US8053407B2 (en) 2011-11-08
ATE450268T1 (de) 2009-12-15
EP2311483A1 (en) 2011-04-20
CN101693107A (zh) 2010-04-14
DE60330390D1 (de) 2010-01-14

Similar Documents

Publication Publication Date Title
RU2008146718A (ru) Способы лечения неврологических состояний с применением гематопоэтических факторов роста
ES2180624T3 (es) Co-administracion de mutantes de interleuquina-3 con factores estimulantes de colonias.
DK0579672T3 (da) Xylanase, tilsvarende rekombinant DNA-sekvens, xylanaseholdigt middel og anvendelse af midlet
DE69824755D1 (de) Cytokinähnliches polypeptid-10 aus säugetieren
AU9084601A (en) G-csf analog compositions and methods
FI961630A (fi) Terapeuttisia aineita
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
WO2004058287A3 (en) Methods of treating neurological conditions with hematopoeitic growth factors
ES2055684T3 (es) Un metodo para preparar un agente para el tratamiento de la leucopenia.
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
HUT55036A (en) Process for producing polypeptides blocking the calcium duct
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
PT742720E (pt) Co-administracao de polipeptideos mutantes de interleuquina-3 com csf's para producao de celulas hematopoieticas multi-linhagem
DE69132051D1 (de) Verwendung des rekombinanten koloniestimulierenden faktors-1
EP0672684A4 (en) NOVEL STIMULATION FACTOR OF MEGACARYOCYTATIC COLONIES AND PRODUCTION THEREOF.
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
ATE251640T1 (de) Neues chondrozytprotein
NZ323207A (en) Hemoregulatory compounds

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130306